

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/AC3E6A3499C7EN.html>

Date: November 2022

Pages: 159

Price: US\$ 3,500.00 (Single User License)

ID: AC3E6A3499C7EN

Abstracts

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

According to the recently published report, Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) pipeline Target constitutes close to 70 molecules. Out of which approximately 59 molecules are developed by companies and remaining by the universities/institutes.

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Alpha-synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson's. In Parkinson's it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It reduces neuronal responsiveness to various apoptotic stimuli, leading to decreased caspase-3 activation.

The report outlays comprehensive information on the Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics, complete with analysis by indications, stage of

development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 8, 28 and 16 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 9 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Metabolic Disorders, Cardiovascular, Gastrointestinal, Infectious Disease and Ophthalmology which include indications Parkinson's Disease, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), Lewy Body Dementia, Alzheimer's Disease, Neurodegenerative Diseases, Familial Amyloid Neuropathies, Amyloidosis, Autism, Chronic Traumatic Encephalopathy (CTE), Constipation, Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration), Dementia, Dementia Associated With Alzheimer's Disease, Frontotemporal Dementia (FTD), Glaucoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Progressive Supranuclear Palsy, Psychosis, Spinal Cord Injury, Stroke, Traumatic Brain Injury and Type 2 Diabetes.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)

The report reviews Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics and enlists all their major and minor projects

The report assesses Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Overview

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Companies Involved in Therapeutics

Development

ABL Bio Inc

AC Immune SA

Alterity Therapeutics Ltd

Annovis Bio Inc

Aprinoia Therapeutics Inc

Arvinas Inc

AstraZeneca Plc

AUM LifeTech Inc

BioArctic AB

Chimerna Therapeutics Inc

DegenRx BV

Denali Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Co

Enterin Inc

Fulcrum Therapeutics Inc

Genmab AS

ICB International Inc

Ionis Pharmaceuticals Inc
ND Biosciences SA
Neuramedy Co Ltd
Neurimmune Holding AG
Neuropore Therapies Inc
nLife Therapeutics SL
Nuravax Inc
Prazer Therapeutics
Priavoid GmbH
Primary Peptides Inc
Proclara Biosciences Inc
ProMIS Neurosciences Inc
Prothena Corp Plc
ResQ Biotech
Seelos Therapeutics, Inc.
Selonterra Inc
Shape Therapeutics Inc
Synapss Therapeutics Inc
Teva Pharmaceutical Industries Ltd
Trementis Corp
UCB SA
UniQure NV
Vaxxinity Inc
Wren Therapeutics Ltd
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of
Amyloid Precursor or NACP or SNCA) - Drug Profiles
AAV hmAb 1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ABBV-0805 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ABL-301 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ACI-5755 - Drug Profile

Product Description
Mechanism Of Action
History of Events
ACI-7104 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AHT-434 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Alpha Syn Degradar - Drug Profile
Product Description
Mechanism Of Action
Alpha Synuclein - Drug Profile
Product Description
Mechanism Of Action
History of Events
Alpha-Synuclein - Drug Profile
Product Description
Mechanism Of Action
AMT-210 - Drug Profile
Product Description
Mechanism Of Action
Antibodies to Inhibit Alpha-Synuclein for Glaucoma - Drug Profile
Product Description
Mechanism Of Action
Antisense RNAi Oligonucleotide to Inhibit Alpha Synuclein for Parkinson's Disease -
Drug Profile
Product Description
Mechanism Of Action
History of Events
Antisense RNAi Oligonucleotides to Inhibit Alpha Synuclein for Parkinson's Disease -
Drug Profile
Product Description
Mechanism Of Action
History of Events
ANVS-405 - Drug Profile
Product Description

Mechanism Of Action

History of Events

Aptamer to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

ASOA-19 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ATV:aSyn - Drug Profile

Product Description

Mechanism Of Action

AV-1950D - Drug Profile

Product Description

Mechanism Of Action

AV-1950R - Drug Profile

Product Description

Mechanism Of Action

buntanetap tartrate - Drug Profile

Product Description

Mechanism Of Action

History of Events

C-terminal Alpha Synuclein - Drug Profile

Product Description

Mechanism Of Action

CLR-01 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Drug to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

History of Events

ENT-01 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Fusion Proteins to Inhibit ABPP, MAPT and NACP for Amyloidosis and Neurodegenerative Diseases - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

ION-464 - Drug Profile

Product Description

Mechanism Of Action

History of Events

LuAF-82422 - Drug Profile

Product Description

Mechanism Of Action

History of Events

MEDI-1341 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Monoclonal Antibodies to Inhibit Alpha Synuclein for Multiple System Atrophy - Drug Profile

Product Description

Mechanism Of Action

History of Events

Monoclonal Antibodies to Inhibit Tau, Amyloid Beta and Alpha-Synuclein for Neurodegenerative Diseases - Drug Profile

Product Description

Mechanism Of Action

Morphomer a-Syn - Drug Profile

Product Description

Mechanism Of Action

ND-001 - Drug Profile

Product Description

Mechanism Of Action

NLFPD-1233 - Drug Profile

Product Description

Mechanism Of Action

History of Events

NM-401 - Drug Profile

Product Description

Mechanism Of Action

NM-402 - Drug Profile

Product Description

Mechanism Of Action

NM-403 - Drug Profile

Product Description

Mechanism Of Action

NPT-088 - Drug Profile

Product Description

Mechanism Of Action

History of Events

NPT-10018A - Drug Profile

Product Description

Mechanism Of Action

NPT-189 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

History of Events

Parkinson's Disease (SNCA A53T, LRRK2 G2019S) - Drug Profile

Product Description

Mechanism Of Action

PD-04 - Drug Profile

Product Description

Mechanism Of Action

History of Events

PD-1601 - Drug Profile

Product Description

Mechanism Of Action

History of Events

PD-1602 - Drug Profile

Product Description

Mechanism Of Action

History of Events

PMN-442 - Drug Profile

Product Description

Mechanism Of Action

History of Events

PP-003 - Drug Profile

Product Description

Mechanism Of Action

PR-004 - Drug Profile

Product Description

Mechanism Of Action

History of Events

prasinezumab - Drug Profile

Product Description

Mechanism Of Action

History of Events

PRI-100 - Drug Profile

Product Description

Mechanism Of Action

PRX-303 - Drug Profile

Product Description

Mechanism Of Action

Recombinant Peptides to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

SHP-201 - Drug Profile

Product Description

Mechanism Of Action

SLS-004 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SLS-007 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit SNCA for Parkinson's Disease - Drug Profile

Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit Alpha Synuclein for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Alpha-Synuclein and Lcn2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
SMQ-1001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SNP-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TEV-56286 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TEV-56287 - Drug Profile
Product Description
Mechanism Of Action
History of Events
UB-312 - Drug Profile
Product Description
Mechanism Of Action

History of Events

UCB-0599 - Drug Profile

Product Description

Mechanism Of Action

History of Events

UCB-7853 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Dormant Products

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Discontinued Products

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Product Development Milestones

Featured News & Press Releases

Nov 07, 2022: Alterity Therapeutics announces presentation of data from the bioMUSE natural history study at the American Autonomic Society Annual Meeting

Oct 26, 2022: Alterity Therapeutics announces presentation of MRI data from the bioMUSE natural history study at the American Neurological Association Annual Meeting

Oct 14, 2022: Alterity Therapeutics obtains approval in Australia to begin MSA therapy

Oct 11, 2022: Annovis Bio announces publication of phase 2a clinical data in The Journal of Prevention of Alzheimer's Disease

Oct 06, 2022: Annovis Bio announces FDA authorization to proceed with phase 2/3 trial for buntanetap in Alzheimer's Disease

Sep 26, 2022: Alterity Therapeutics announces presentation of wearable sensor data from the bioMUSE natural history study at the International Congress of Parkinson's Disease and Movement Disorders

Sep 20, 2022: Alterity Therapeutics receives U.S. FDA approval for Investigational New Drug application for ATH434 for the treatment of Multiple System Atrophy

Sep 13, 2022: Annovis Bio announces publication of patents covering the treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases

Aug 25, 2022: Alterity begins Phase II multiple system atrophy therapy trial in UK

Aug 24, 2022: Annovis Bio doses first subject in Phase III Parkinson's trial

Aug 24, 2022: Seelos Therapeutics receives a research and development grant from The Michael J. Fox Foundation for Parkinson's Research for SLS-004

Jul 08, 2022: Annovis Bio receives FDA notice to advance Phase III Parkinson's trial

Jul 06, 2022: Alterity Therapeutics doses first patient in ATH434 phase 2 clinical trial in

multiple system atrophy

Jun 30, 2022: Alterity receives a \$4.1 million R&D Tax Incentive Refund

Jun 24, 2022: Alterity obtains authorisation in Italy for Phase II trial of multiple system atrophy therapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by ABL Bio Inc, 2022
Pipeline by AC Immune SA, 2022
Pipeline by Alterity Therapeutics Ltd, 2022
Pipeline by Annovis Bio Inc, 2022
Pipeline by Aprinoia Therapeutics Inc, 2022
Pipeline by Arvinas Inc, 2022
Pipeline by AstraZeneca Plc, 2022
Pipeline by AUM LifeTech Inc, 2022
Pipeline by BioArctic AB, 2022
Pipeline by Chimerna Therapeutics Inc, 2022
Pipeline by DegenRx BV, 2022
Pipeline by Denali Therapeutics Inc, 2022
Pipeline by Eisai Co Ltd, 2022
Pipeline by Eli Lilly and Co, 2022
Pipeline by Enterin Inc, 2022
Pipeline by Fulcrum Therapeutics Inc, 2022
Pipeline by Genmab AS, 2022
Pipeline by ICB International Inc, 2022
Pipeline by Ionis Pharmaceuticals Inc, 2022
Pipeline by ND Biosciences SA, 2022
Pipeline by Neuramedy Co Ltd, 2022
Pipeline by Neurimmune Holding AG, 2022

Pipeline by Neuropore Therapies Inc, 2022
Pipeline by nLife Therapeutics SL, 2022
Pipeline by Nuravax Inc, 2022
Pipeline by Prazer Therapeutics, 2022
Pipeline by Priavoid GmbH, 2022
Pipeline by Primary Peptides Inc, 2022
Pipeline by Proclara Biosciences Inc, 2022
Pipeline by ProMIS Neurosciences Inc, 2022
Pipeline by Prothena Corp Plc, 2022
Pipeline by ResQ Biotech, 2022
Pipeline by Seelos Therapeutics, Inc., 2022
Pipeline by Selonterra Inc, 2022
Pipeline by Shape Therapeutics Inc, 2022
Pipeline by Synapss Therapeutics Inc, 2022
Pipeline by Teva Pharmaceutical Industries Ltd, 2022
Pipeline by Treventis Corp, 2022
Pipeline by UCB SA, 2022
Pipeline by UniQure NV, 2022
Pipeline by Vaxxinity Inc, 2022
Pipeline by Wren Therapeutics Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/AC3E6A3499C7EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AC3E6A3499C7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970